Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02197767|
Recruitment Status : Completed
First Posted : July 23, 2014
Results First Posted : February 6, 2019
Last Update Posted : February 6, 2019
|Condition or disease||Intervention/treatment||Phase|
|Fibrillary Glomerulonephritis||Drug: rituximab||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||11 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Single Center Pilot Trial of Rituximab in the Treatment of Fibrillary Glomerulonephritis|
|Study Start Date :||November 2014|
|Actual Primary Completion Date :||April 2017|
|Actual Study Completion Date :||April 2017|
rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
1000 mg infusion
Other Name: Rituxan
- Change in 24 Hour Creatinine Clearance [ Time Frame: Day 0, Day 365 ]Change in 24 hour creatinine clearance with the use of rituximab at 12 months. Creatinine clearance results are reported as milliliters/minute/patient's body surface area (mL/min/SA).
- Change in Proteinuria [ Time Frame: Day 0, Day 365 ]Change in proteinuria in milligrams (mg) with the use of rituximab at 12 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02197767
|United States, Minnesota|
|Mayo Clinic in Rochester|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Stephen B. Erickson, M.D.||Mayo Clinic|